Novartis Sues Noven To Block Generic Dementia Patch

Law360, New York (April 3, 2013, 6:49 PM EDT) -- Novartis AG slapped Hisamitsu Pharmaceutical Co. Inc. and subsidiary Noven Pharmaceuticals Inc. with a lawsuit in Delaware on Wednesday, claiming Noven infringed two patents by seeking U.S. regulatory approval for a generic version of Novartis' dementia-treating Exelon patch.

Novartis and patent co-owner LTS Lohmann Therapie-Systeme AG's complaint against Japan-based Hisamitsu and two Noven units asked the court for injunctive relief as well as an order declaring that U.S. Food and Drug Administration approval of Noven's proposed rivastigmine transdermal system can't come before the plaintiffs' rights under...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.